Recent pre-clinical studies in mice show that glucagon blockers can improve heart function in HFpEF, a type of heart failure.

Hypothesis: We tested the hypothesis that oral H 2 S donor (SG-1002) therapy would restore critical aspects of skeletal muscle metabolism and exercise performance in cardiometabolic HFpEF. Results: SG ...

Mavacamten, a drug initially developed to treat hypertrophic cardiomyopathy, has shown signs of reducing heart stress in ...

FRIDAY, Sept. 20, 2024 (HealthDay News) -- For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ventricular (LV) diastolic function ...

The novel investigational weight loss agent HU6 had mixed results specifically targeting obesity-related heart failure with ...

Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

FRIDAY, Sept. 20, 2024 (HealthDay News) -- For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ventricular (LV) diastolic function, ...

Understanding how patients with heart failure with preserved ejection fraction (HFPEF) die provides insight ... better prediction of response to therapy in designing clinical trials.

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ventricular (LV) diastolic function, according to a study published online Sept.

Novel therapies for HFmrEF and HFpEF aim to improve symptom management and patient outcomes, addressing current treatment limitations. Emerging treatments could reduce hospitalization rates and ...